Forfatterne, innholdet og redaksjonen presenteres
So when I started learning about these medications and started my GLP-1 at 200lbs (qualifying with a BMI 30 with a comorbidity of hypertension), I would have been thrilled to not lose a single pound if only to not have such a hard time maintaining
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
Indian companies are also developing a biosimilar for semaglutide where it seems that the patent will not be respected after 2026
The top ten factors for employers when considering GLP-1 coverage for weight loss are: Obesity as a risk factor for chronic diseases and associated costs53% Long-term costs and difficulty measuring outcomes38% Impact/effectiveness of cost-control mechanisms on health insurance premiums38% Medication adherence factors25% Immediate/short-term costs25% Broker/consultant/PBM recommendations25% Patient and prescriber demand22% Oral pill forms available22% GLP-1 label expansion/approval for secondary conditions22% Side effects19%
For obesity-driven low testosterone, treating the cause has an advantage replacement cant match: it preserves fertility
